The global Biological Safety Testing Market Study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product & Services (Consumables, Instrument, Services), By Application (Vaccine Development and Manufacturing, Monoclonal Antibodies Development and Manufacturing, Cellular & Gene Therapy Products Development and Manufacturing, Blood and Blood Products Development and Manufacturing, Others), By Test (Endotoxin Test, Sterility Test, Mycoplasma Tests, Bioburden Tests, Residual Host-cell Proteins & DNA Detection Tests, Virus safety Test, Others).
The Biological Safety Testing Market focuses on testing, validation, and assessment of biological products, pharmaceuticals, vaccines, and medical devices to ensure safety, quality, and regulatory compliance in healthcare and life sciences industries. In 2024, biological safety testing includes methods such as sterility testing, endotoxin testing, cell-based assays, and microbial limit testing to evaluate product integrity, purity, and efficacy, supporting product development, manufacturing processes, and regulatory submissions. With considerations for patient safety, product quality control, and risk mitigation, the biological safety testing market plays a critical role in pharmaceutical development, biomanufacturing, and healthcare product safety.
The global Biological Safety Testing Industry is highly competitive with a large number of companies focusing on niche market segments. Amidst intense competitive conditions, Biological Safety Testing Companies are investing in new product launches and strengthening distribution channels. Key companies operating in the Biological Safety Testing Industry include- Avance Biosciences, Biomerieux SA, Cytovance Biologics, Eurofins Scientific, Lonza, Merck KGaA, Promega Corp, Thermo Fisher Scientific Inc, Toxikon, WuXi AppTec.
The adoption of in vitro testing methods is a prominent trend in biological safety testing. In vitro assays offer efficient, cost-effective, and ethically sound alternatives to traditional animal-based testing for evaluating the safety and efficacy of biopharmaceuticals, vaccines, and medical devices. These methods utilize cell cultures, tissue models, and molecular assays to assess biological responses, toxicity profiles, and immunogenicity risks, providing relevant data for regulatory submissions and product approvals. Regulatory agencies and industry stakeholders increasingly prioritize the use of in vitro testing to ensure product safety while reducing reliance on animal testing, driving market adoption of innovative in vitro technologies and platforms.
Stringent regulatory guidelines serve as a primary driver for the biological safety testing market. Regulatory authorities such as the FDA, EMA, and WHO enforce rigorous requirements for the assessment of biopharmaceutical product safety, purity, and potency throughout the development lifecycle. Compliance with regulatory standards, including Good Manufacturing Practice (GMP) regulations and International Conference on Harmonization (ICH) guidelines, is essential for obtaining marketing authorization and ensuring product quality and patient safety. The evolving regulatory landscape, coupled with increasing scrutiny on biopharmaceutical safety, stimulates demand for comprehensive biological safety testing services, driving market growth and investment in advanced testing methodologies and infrastructure.
An opportunity for market expansion lies in the expansion of biopharmaceutical manufacturing facilities and capabilities. The growing demand for biologic drugs, including monoclonal antibodies, vaccines, and cell therapies, necessitates the establishment of robust manufacturing processes and quality control systems to ensure product safety and consistency. Biological safety testing plays a critical role in quality assurance and batch release testing for biopharmaceuticals, driving demand for specialized testing services and analytical technologies. Investing in state-of-the-art manufacturing facilities, automated testing platforms, and skilled workforce development enables companies to meet the increasing demand for biologic drugs while maintaining compliance with regulatory requirements, fostering growth opportunities in the biological safety testing market.
Services emerge as the fastest-growing segment within the biological safety testing market. This growth is fueled by several factors, including the increasing outsourcing of biological safety testing services by pharmaceutical and biotechnology companies, as well as academic and research institutions. As the demand for biologics, vaccines, monoclonal antibodies, cellular and gene therapy products, and blood products continues to rise, there is a corresponding need for rigorous safety testing to ensure product quality and compliance with regulatory standards. Biological safety testing services encompass a wide range of activities, including endotoxin testing, sterility testing, mycoplasma testing, bioburden testing, residual host-cell proteins and DNA detection tests, virus safety testing, and others. Outsourcing these services to specialized testing laboratories and contract research organizations (CROs) allows companies to access specialized expertise, state-of-the-art facilities, and regulatory compliance, while also enabling them to focus on core research and development activities. Moreover, the complexity and diversity of biological products and the stringent regulatory requirements governing their development and manufacturing further drive the demand for biological safety testing services. With the continued growth of the biopharmaceutical industry and the increasing emphasis on product safety and quality, the services segment of the biological safety testing market is expected to experience sustained expansion in the coming years.
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
Geographical Analysis
North America (United States, Canada, Mexico)
Europe (Germany, France, United Kingdom, Spain, Italy, Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Rest of Asia Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East and Africa (Saudi Arabia, UAE, Rest of Middle East, South Africa, Egypt, Rest of Africa)
Avance Biosciences
Biomerieux SA
Cytovance Biologics
Eurofins Scientific
Lonza
Merck KGaA
Promega Corp
Thermo Fisher Scientific Inc
Toxikon
WuXi AppTec
* List not Exhaustive
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biological Safety Testing Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biological Safety Testing Industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Biological Safety Testing Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Biological Safety Testing Market Size Outlook, $ Million, 2021 to 2030
3.2 Biological Safety Testing Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biological Safety Testing Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biological Safety Testing Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biological Safety Testing Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Biological Safety Testing Industry
4.2 Key Market Trends in Biological Safety Testing Industry
4.3 Potential Opportunities in Biological Safety Testing Industry
4.4 Key Challenges in Biological Safety Testing Industry
5 Market Factor Analysis
5.1 Value Chain Analysis
5.2 Competitive Landscape
5.2.1 Global Biological Safety Testing Market Share by Company (%), 2023
5.2.2 Product Offerings by Company
5.3 Porter’s Five Forces Analysis
5.4 Pricing Analysis and Outlook
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Biological Safety Testing Market Outlook by Segments
7.1 Biological Safety Testing Market Outlook by Segments, $ Million, 2021- 2030
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
8 North America Biological Safety Testing Market Analysis and Outlook To 2030
8.1 Introduction to North America Biological Safety Testing Markets in 2024
8.2 North America Biological Safety Testing Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biological Safety Testing Market size Outlook by Segments, 2021-2030
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
9 Europe Biological Safety Testing Market Analysis and Outlook To 2030
9.1 Introduction to Europe Biological Safety Testing Markets in 2024
9.2 Europe Biological Safety Testing Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biological Safety Testing Market Size Outlook by Segments, 2021-2030
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
10 Asia Pacific Biological Safety Testing Market Analysis and Outlook To 2030
10.1 Introduction to Asia Pacific Biological Safety Testing Markets in 2024
10.2 Asia Pacific Biological Safety Testing Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biological Safety Testing Market size Outlook by Segments, 2021-2030
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
11 South America Biological Safety Testing Market Analysis and Outlook To 2030
11.1 Introduction to South America Biological Safety Testing Markets in 2024
11.2 South America Biological Safety Testing Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biological Safety Testing Market size Outlook by Segments, 2021-2030
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
12 Middle East and Africa Biological Safety Testing Market Analysis and Outlook To 2030
12.1 Introduction to Middle East and Africa Biological Safety Testing Markets in 2024
12.2 Middle East and Africa Biological Safety Testing Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biological Safety Testing Market size Outlook by Segments, 2021-2030
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Avance Biosciences
Biomerieux SA
Cytovance Biologics
Eurofins Scientific
Lonza
Merck KGaA
Promega Corp
Thermo Fisher Scientific Inc
Toxikon
WuXi AppTec
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product & Services
Consumables
Instrument
Services
By Application
Vaccine Development and Manufacturing
Monoclonal Antibodies Development and Manufacturing
Cellular & Gene Therapy Products Development and Manufacturing
Blood and Blood Products Development and Manufacturing
Others
By Test
Endotoxin Test
Sterility Test
Mycoplasma Tests
Bioburden Tests
Residual Host-cell Proteins & DNA Detection Tests
Virus safety Test
Others
The global Biological Safety Testing Market is one of the lucrative growth markets, poised to register a 10.2% growth (CAGR) between 2024 and 2030.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Avance Biosciences, Biomerieux SA, Cytovance Biologics, Eurofins Scientific, Lonza, Merck KGaA, Promega Corp, Thermo Fisher Scientific Inc, Toxikon, WuXi AppTec
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume